Last reviewed: May 21, 2026 Last updated: May 21, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
The report highlights early metabolic studies, selected clinical trials, and certain double-blind placebo-controlled investigations that examined markers such as: blood sugar regulation insulin sensitivity cholesterol levels impaired glucose tolerance adipose tissue activity fat release and lipolytic activity While these studies generated interest in AOD-9604 as a potential anti-obesity drug candidate , the report stresses that no authority recognizes it as an active treatment for obesity, weight loss, or human use and emphasizes that it remains designated strictly for research use
Inositol has been studied as a potential treatment option for many conditions
This level of selectivity makes it a good choice for researchers
HCG: A Separate Conversion Standard HCG is also commonly dosed in IU, but its biological standard is distinct from HGH's
Clinical trials document headache incidence ranging from 515% depending on the medication, dose, and study population
